Loading...
Search for:
3-methyl-2-oxovaleric-acid
0.006 seconds
Metabonomics exposes metabolic biomarkers of Crohn's disease by 1HNMR
, Article Gastroenterology and Hepatology from Bed to Bench ; Volume 6, Issue SUPPL , 2013 , Pages S19-S22 ; 2008-4234 (EISSN) ; Ektefa, F ; Hagh-Azali, M ; Aghdaie, H. A ; Sharif University of Technology
2013
Abstract
Metabonomics and other "omic" fields are essential science in analytical chemistry. Modern analytical instruments such as proton nuclear magnetic resonance (1H-NMR) can provide the great quantity of analytical information. In order to assign unknown samples, chemometric methods recognition build classification model based on experimental data. Firstly, some current strategies regarding disease diagnosis are exhibited in metabonomic studies. Some diseases such as crohn's disease can be difficult to diagnose since its signs and symptoms may be similar to other medical problems or often mimic other symptoms. Applications of NMR and supervised pattern recognition in the field of metabonomics are...
A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
, Article European Journal of Clinical Nutrition ; Volume 73, Issue 9 , 2019 , Pages 1224-1235 ; 09543007 (ISSN) ; Mirhafez, S. R ; Dehabeh, M ; Hariri, M ; Azimi Nezhad, M ; Nobakht M. Gh, B. F ; Sharif University of Technology
Nature Publishing Group
2019
Abstract
Background/Objectives: Curcumin, a natural polyphenol compound in the spice turmeric, has been found to have potent anti-oxidative and anti-inflammatory activity. Curcumin may treat non-alcoholic fatty liver disease (NAFLD) through its beneficial effects on biomarkers of oxidative stress (OS) and inflammation, which are considered as two feature of this disease. However, the effects of curcumin on NAFLD have been remained poorly understood. This investigation evaluated the effects of administrating curcumin on metabolic status in NAFLD patients. Subjects/Methods: Fifty-eight NAFLD patients participated in a randomized, double-blind, placebo-controlled parallel design of study. The subjects...